Glenmark Life Sciences Limited IPO
Glenmark Life Sciences Limited IPO is listed on BSE and NSE, priced at ₹695–₹720 per share. The stock debuted at ₹750, delivering a listing gain of 4.2%. The IPO had a lot size of ₹20 shares and a minimum investment of ₹14,400.
Glenmark Life Sciences Limited IPO
- IPO Dates
- Jul 27, 2021 – Jul 29, 2021
- Price band
- ₹695-720 per equity share
- Minimum Investment
- ₹14,400
- Issue size
- 1513.60 Crore; 1060 Crore Fresh Issue + 453.60 Crore Offer for Sale of 63,00,000 Shares
- Lot size
- 20
- Allotment Date
- Aug 3, 2021
- Listing
- Aug 6, 2021
- Listing At
- BSE, NSE
IPO timeline
-
Jul 27, 2021
Open Date
Completed
-
Jul 29, 2021
Close Date
Completed
-
Aug 3, 2021
Allotment Date
Completed
-
Aug 6, 2021
Listing Date
Completed
Price Summary
- Last closing
- 1,086.00 (50.83%)
- 52 week high
- 1,335.10
- 52 week low
- 676.50
- Last update
Glenmark Life Sciences Limited IPO Essentials
Glenmark Life Sciences Limited IPO Details
Glenmark Life Sciences Limited IPO is priced at ₹695-720 per share with a total issue size of 1513.60 Crore; 1060 Crore Fresh Issue + 453.60 Crore Offer for Sale of 63,00,000 Shares. The IPO has a lot size of 20 shares and is listed on BSE and NSE.
- Issue price
- ₹695-720 per equity share
- Lot size
- 20 shares
- Face value
- ₹2 Per Equity Share
- Issue size
- 1513.60 Crore; 1060 Crore Fresh Issue + 453.60 Crore Offer for Sale of 63,00,000 Shares
- Listing at
- BSE, NSE
- List price
- 750.0(NSE)
- Listing date
- Registrar
- KFintech Private Limited
- Lead manager
-
BoA Merrill Lynch, BOB Capital Markets Limited, DAM Capital Advisors Ltd (Formerly IDFC Securities Ltd), Goldman Sachs (India) Securities Private Limited, Kotak Mahindra Capital Company Limited, SBI Capital Markets Limited
Glenmark Life Sciences Limited IPO Analytics
Glenmark Life Sciences Limited IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.
Glenmark Life Sciences Limited IPO Subscription Status
Glenmark Life Sciences Limited IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.
The IPO subscription status indicates investor demand across categories.
| As on | QIB |
NII
|
Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 42,42,379 |
32,32,770
|
75,43,130 | 1,50,18,279 |
|
Day 1
27-07-20 05:00 PM
|
0.00 x |
0.85x
|
5.17 x | 2.78 x |
|
Day 2
28-07-20 05:00 PM
|
1.40 x |
3.48x
|
9.51 x | 5.90 x |
|
Day 3
29-07-20 05:00 PM
|
37.30 x |
125.62x
|
15.00 x | 45.08 x |
|
Total No. of Applications
|
category wise applications | ||
|---|---|---|---|
| 3950392 (Approx) | 10.74 | ||
Glenmark Life Sciences Limited Valuations
Earnings
- EPS (Post IPO)
- ₹32.61/-
- P/E Ratio
- 25.13
Returns
- RoNW
- 46.71%
Glenmark Life Sciences Limited Financials( In Crs.)
| 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | |
|---|---|---|---|
| Assets | 1,997.07 | 1,725.60 | 1,475.39 |
| Revenue | 1,885.97 | 1,549.30 | 886.86 |
| Profit After Tax | 351.58 | 313.09 | 195.59 |
Glenmark Life Sciences Limited Company & Offer Insights
About Glenmark Life Sciences Limited
Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.
Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.
Glenmark Life Sciences Limited Promoter(s)
Glenmark Pharmaceuticals Limited are the company's promoters of Glenmark Life Sciences Limited.
Glenmark Life Sciences Limited IPO Issue Objectives
- •
- To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.
- •
- To finance capital expenditure requirements.
- •
- To meet general corporate purposes.
Glenmark Life Sciences Limited IPO - Anchor Investors
Glenmark Life Sciences mobilises Rs 454 crore from anchor investors ahead of IPO
HSBC Global Investment Funds, Government Pension Fund Global, Oaktree Emerging Markets Equity Fund LP, Copthall Mauritius Investment Ltd -ODI account, Societe Generale-ODI, Kuber India Fund and Reliance General Insurance Company are among the anchor investors.
Glenmark Life Sciences Limited IPO - Peers Comparison
| P/B Ratio | P/E Ratio | RoNW | Revenue(in Cr.) | |
|---|---|---|---|---|
| Glenmark Lifesciences Limited | 10.31 | 25.13 | 46.71% | 1,859.76 |
| Divis Laboratories Limited | 12.95 | 61.40 | 210% | 7,031.96 |
| Laurus Labs Limited | 22.06 | 77.45 | 15.56% | 4,835.86 |
| Shilpa Medicare Limited | 7.15 | 42.08 | 17.00% | 931.27 |
| Aarti Drugs Limited | 5.12 | 287.45 | 1.78% | 2,159.31 |
| Solara Active Pharma Sciences Limited | 6.85 | 46.59 | 14.69% | 1,645.65 |
Contact Information
Frequently Asked Questions
Click any question to reveal the answer
Glenmark Life Sciences Limited IPO is a book-built IPO worth ₹1513.60 Crore; 1060 Crore Fresh Issue + 453.60 Crore Offer for Sale of 63,00,000 Shares. The price band is ₹695–₹720 per share. The IPO opens on Jul 27, 2021 and closes on Jul 29, 2021. It will be listed on BSE and NSE. KFintech Private Limited is the registrar.
The price band of Glenmark Life Sciences Limited IPO is ₹695 to ₹720 per share.
The lot size of Glenmark Life Sciences Limited IPO is 20 shares.
The minimum investment for Glenmark Life Sciences Limited IPO is approximately ₹14,400 based on the upper price band .
Glenmark Life Sciences Limited IPO opens on Jul 27, 2021 and closes on Jul 29, 2021.
The allotment date of Glenmark Life Sciences Limited IPO is Aug 3, 2021.
Glenmark Life Sciences Limited IPO is expected to be listed on Aug 6, 2021, on BSE and NSE .
Glenmark Life Sciences Limited IPO listed on Aug 6, 2021. It was issued at ₹750.0(NSE) and is currently around ₹1086.00 as on 17-Jan-2025 3:30 PM, which is approximately 50.8% versus issue price. The 52-week high is ₹1,335.10.
Based on listing and post-listing performance, Glenmark Life Sciences Limited IPO delivered around 50.8% over issue price. Whether it was worth applying depends on your risk profile, allocation, and holding horizon.
To buy Glenmark Life Sciences Limited IPO shares after listing, log in to your broker app (such as Zerodha, Angel One, Groww, Upstox, ICICI Direct), search the stock symbol, place a delivery/CNC order, and confirm quantity and price.
Glenmark Life Sciences Limited IPO valuation snapshot: P/E 25.13, EPS ₹32.61/-, P/B N/A, RoNW 46.71%, and market cap N/A.
To apply for Glenmark Life Sciences Limited IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Glenmark Life Sciences Limited IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Glenmark Life Sciences Limited IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Glenmark Life Sciences Limited IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Glenmark Life Sciences Limited IPO allotment status on IPO Ji for quick and easy access.